168 related articles for article (PubMed ID: 26137891)
21. Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy.
Yoo JW; Jo KW; Kang BH; Kim MY; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
Eur Respir J; 2014 Nov; 44(5):1289-95. PubMed ID: 25102962
[TBL] [Abstract][Full Text] [Related]
22. Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
Kurt OK; Kurt B; Talay F; Tug T; Soy M; Bes C; Hayran M
Wien Klin Wochenschr; 2013 Oct; 125(19-20):616-20. PubMed ID: 24061693
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
24. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
25. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
[TBL] [Abstract][Full Text] [Related]
26. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
27. An evaluation of the tuberculin skin test for anti TNF alpha prophylaxis in patients with ankylosing spondylitis and rheumatoid arthritis.
Karkucak M; Capkin E; Ozsu S; Nuhoglu I; Erol M; Yilmaz G; Gokmen F
Bratisl Lek Listy; 2010; 111(9):498-501. PubMed ID: 21180264
[TBL] [Abstract][Full Text] [Related]
28. Risk of significant infection in rheumatoid arthritis patients switching anti-tumor necrosis factor-α drugs.
Nguyen-Khoa BA; Goehring EL; Alexander KA; Dong W; Napalkov P; Jones JK
Semin Arthritis Rheum; 2012 Oct; 42(2):119-26. PubMed ID: 22595643
[TBL] [Abstract][Full Text] [Related]
29. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.
Aggarwal R; Manadan AM; Poliyedath A; Sequeira W; Block JA
J Rheumatol; 2009 May; 36(5):914-7. PubMed ID: 19332623
[TBL] [Abstract][Full Text] [Related]
30. Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study.
Aydin V; Akici A; Isli F; Aksoy M; Aydin M; Gursoz H
J Clin Pharm Ther; 2019 Aug; 44(4):553-560. PubMed ID: 30763469
[TBL] [Abstract][Full Text] [Related]
31. Prophylaxis for latent tuberculosis infection prior to anti–tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis.
Hazlewood GS; Naimark D; Gardam M; Bykerk V; Bombardier C
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1722-31. PubMed ID: 23836530
[TBL] [Abstract][Full Text] [Related]
32. Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan.
Liao TL; Lin CH; Chen YM; Chang CL; Chen HH; Chen DY
PLoS One; 2016; 11(4):e0153217. PubMed ID: 27064275
[TBL] [Abstract][Full Text] [Related]
33. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
Theis VS; Rhodes JM
Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
[TBL] [Abstract][Full Text] [Related]
34. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay.
Chen DY; Shen GH; Chen YM; Chen HH; Hsieh CW; Lan JL
Ann Rheum Dis; 2012 Feb; 71(2):231-7. PubMed ID: 22021896
[TBL] [Abstract][Full Text] [Related]
35. Frequency of latent tuberculosis in patients receiving Anti-TNF-Alpha therapy.
Coşkunol İ; Turan O; Baysak A; Solmaz D; Can G
Afr Health Sci; 2023 Jun; 23(2):128-132. PubMed ID: 38223592
[TBL] [Abstract][Full Text] [Related]
36. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.
Mohan AK; Coté TR; Block JA; Manadan AM; Siegel JN; Braun MM
Clin Infect Dis; 2004 Aug; 39(3):295-9. PubMed ID: 15306993
[TBL] [Abstract][Full Text] [Related]
37. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis.
Inanc N; Aydin SZ; Karakurt S; Atagunduz P; Yavuz S; Direskeneli H
J Rheumatol; 2009 Dec; 36(12):2675-81. PubMed ID: 19918035
[TBL] [Abstract][Full Text] [Related]
38. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
Sfikakis PP; Iliopoulos A; Elezoglou A; Kittas C; Stratigos A
Arthritis Rheum; 2005 Aug; 52(8):2513-8. PubMed ID: 16052599
[TBL] [Abstract][Full Text] [Related]
39. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
40. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
Sato S; Nagai H
Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
